medicinal cannabis
medicinal cannabis · page 4
- Opinion
26-Year-Old Dubliner Becomes Ireland’s First ‘Medical Cannabis Access Programme’ Patient
IRELAND now has its first patient through the state-approved Medical Cannabis Access Programme (MCAP) some four years after it was launched – but experts warn the scheme is still unfit for purpose.
- Companies
From Flowers To Pharma – How Europe Is Forging Its Own Medicinal Cannabis Identity
As Europe embraces medicinal cannabis the continent’s prescribing landscape is developing different characteristics to that of the US.
- News
Danish Cultivator Completes New Facility Gearing Itself For ‘High-Volume Production’
STENOCARE has informed investors that the completion of its pharma-grade cultivation facility is an ‘important milestone’ on its journey towards profitability, despite reporting no sales and increasing losses in its third quarter.
- Pharmaceutical
Oxford Cannabinoid Technologies Signs New Agreement With Stemtech
OCT believes Stemtech’s technology provides an in vitro translational model that will better predict results in humans.
- News
Irish Clinical Establishment Continues To Shun Cannabis Leaving Medical Access Programme Doomed to Failure
Drug policy specialist Natalie O’Regan on Ireland’s faltering Medical Cannabis Access Programme THE Medical Cannabis Access Programme (MCAP) was launched in 2017, four years later and the first product is now being made available for patients.
- CBD Market
Kanabo Aiming To Become Europe’s First Cannabis ‘Unicorn’
UK Market-listed cannabis business Kanabo is now generating its first revenues following the successful launch of its flagship VapePod product.
- CBD Market
Is CBD A Boom-Or-Bust Fad – Or A Major FMCG Opportunity?
SUGGESTIONS that CBD is a fad – a boom-to-bust market – with the latter imminent, raised a few eyebrows at Cannabis Europa.
- Medical
Heath Minister Says Lack Of UK Medical Cannabis Scripts Is a Clinical Issue – Not A Political One
DESPITE coming under increasing pressure to unblock the medical cannabis prescribing impasse the UK Government this week continued to distance itself from the issue.
- Pharmaceutical
UK Cannabis Company’s C-Suite Left ‘Shaking Their Heads’ In Disbelief At Company’s Poor Stock Performance
FOLLOWING its listing on the London Stock Exchange in May this year Oxford Cannabinoid Technologies (OCT) has seen more than £20m wiped off its market capitalisation.
- CBD Market
Medical Cannabis Cost-Benefit Analysis Set To Be Launched By UK CIC At A Cost of £30,000
THE initial priorities of the UK Cannabis Industry Council have been identified following a special general meeting attended by around 50 members.
- Opinion
CIC Research Group Looking To Overcome The ‘Scandalous’ Impasse On UK Medical Cannabis Prescribing
Chartered Psychologist and Head of Research at Drug Science, Dr Anne Katrin Schlag, heads up the newly formed Cannabis Industry Council’s (CIC) Research group.
- Adult-Use
US Company Set To Launch UK Medical Cannabis Study In Partnership With Manchester University
A GROUND-BREAKING human pilot study centred on the University of Manchester could provide answers to using cannabis as a pain relief treatment.
